Studying the molecular and cellular effects of a CD19 CAR T cell–mediated elimination of B cells in patients with SLE, thus, provides a unique opportunity to directly learn from precision medicine and better understand the contribution of B cells to the pathogenesis of SLE as part of a reverse translational approach. This evidence concerns the gene CD19 and systemic lupus erythematosus.